And yet, Sanofi’s share price is down about 6.5% this year. Part of that is because the drugmaker canceled several major late-stage programs, raising valid investor concerns about its drug pipeline. Does that spell opportunity now for investors? Let’s see. <\/p>\n
Sanofi beat revenue and earnings expectations in the most recent quarter <\/p>\n
But the company recently posted strong second-quarter results. It earned $1.22 a share on revenue of $13.48 billion, both of which beat analysts’ expectations. And sales of its blockbuster immunology drug, Dupixent, climbed 38% to 5.15 billion euros, surpassing 5 billion euros in a quarter for the first time. <\/p>\n
But investors considering Sanofi’s shares need to look forward, not back. And the company just got some very good news: In July, the U.S. Food and Drug Administration (FDA) approved the company’s on-body injector for isatuximab, sold under the brand name Sarclisa, which treats multiple myeloma, a type of bone marrow and blood cancer. <\/p>\n
As a result, the stock has rebounded in recent weeks and is up about 6% so far in August. <\/p>\n
Wall Street thinks it can continue to climb. The average analyst price target for the stock is $53.72, representing a nearly 18% gain from the current share price. Of the 10 analysts who follow the stock, five rate it a “Buy” and five a “Hold.” <\/p>\n And the stock is inexpensive right now, trading at slightly more than nine times forward earnings. Consider that major drugmakers<\/a> like Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), and Johnson & Johnson<\/a> (NYSE: JNJ) are all trading at more than 20 times forward earnings. <\/p>\n So, for investors looking for stocks trading cheaply relative to peers that deliver a strong dividend yield and have potential for future price appreciation, Sanofi right now checks all the boxes. <\/p>\n Should you buy stock in Sanofi right now? <\/p>\n Before you buy stock in Sanofi, consider this: <\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the\u00a010 best stocks<\/a> for investors to buy now\u2026 and Sanofi wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. <\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation,\u00a0you’d have $443,461!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,307,633!* <\/p>\n Now, it’s worth noting\u00a0Stock Advisor’s total average return is 973% \u2014 a market-crushing outperformance compared to 213% for the S&P 500.\u00a0Don’t miss the latest top 10 list, available with\u00a0Stock Advisor, and join an investing community built by individual investors for individual investors. <\/p>\n See the 10 stocks \u00bb<\/a> <\/p>\n *Stock Advisor returns as of August 26, 2026. <\/p>\n Matthew Benjamin<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Merck. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy<\/a>. <\/p>\n<\/a> Image source: Getty Images. <\/p>\n